Logo Image
|Articles|November 30, 2015

Infinity To Use Medidata RBM in Phase III Oncology Study

Infinity Pharmaceuticals will use Medidata's RBM solution in an upcoming Phase III oncology study for patients with indolent non-Hodgkin lymphoma.

Infinity Pharmaceuticals has expanded its use of the Medidata Clinical Cloud®, by utilizing its risk-based monitoring (RBM) solution in an upcoming Phase III oncology study for patients with indolent non-Hodgkin lymphoma.

Infinity has been a Medidata customer since 2005, utilizing the company’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®) across its pre-clinical and Phase I-III development programs. To further advance its drug development strategy and outsourcing model, Infinity is leveraging the combination of technology and analytics within Medidata RBM-including centralized statistical analytics, targeted source document verification (TSDV), and study and site level key risk indicators (KRIs).

Read the full release.

 

 

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.
Read more